- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00254891
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
March 10, 2015 updated by: Pfizer
International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
PF-3512676 dosing was stopped 20 June 2007 in response to DSMC recommendation to close the trial, citing lack of efficacy concerns as the primary reason with a safety issue (sepsis) also contributing to the decision.
Subjects were allowed to complete standard of care treatment/survival follow-up.
Data collection was completed on 17 July 2008.
Study Type
Interventional
Enrollment (Actual)
828
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Pfizer Investigational Site
-
Camperdown, New South Wales, Australia, 2050
- Pfizer Investigational Site
-
Randwick, New South Wales, Australia, 2031
- Pfizer Investigational Site
-
-
Queensland
-
Pimlico, Queensland, Australia, 4812
- Pfizer Investigational Site
-
Townsville, Queensland, Australia, 4814
- Pfizer Investigational Site
-
Woolloongabba, Queensland, Australia, 4102
- Pfizer Investigational Site
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Pfizer Investigational Site
-
Toorak Gardens, South Australia, Australia, 5065
- Pfizer Investigational Site
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Pfizer Investigational Site
-
East Ringwood, Victoria, Australia, 3135
- Pfizer Investigational Site
-
Wodonga, Victoria, Australia, 3690
- Pfizer Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Pfizer Investigational Site
-
-
-
-
-
Gent, Belgium, 9000
- Pfizer Investigational Site
-
Liège, Belgium, 4000
- Pfizer Investigational Site
-
-
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2A 1A1
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H3G 1A4
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H3T 1E2
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H3T 1M5
- Pfizer Investigational Site
-
Rimouski, Quebec, Canada, G5L 5T1
- Pfizer Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Pfizer Investigational Site
-
-
-
-
-
Beijing, China, 100021
- Pfizer Investigational Site
-
Beijing, China, 100071
- Pfizer Investigational Site
-
Shanghai, China, 200032
- Pfizer Investigational Site
-
-
Liaoning
-
Dalian, Xigang District, Liaoning, China, 116011
- Pfizer Investigational Site
-
-
-
-
-
Nicosia, Cyprus, 2006
- Pfizer Investigational Site
-
-
-
-
-
Nova Ves Pod Plesi, Czech Republic, 26204
- Pfizer Investigational Site
-
Ostrava-Poruba, Czech Republic, 708 52
- Pfizer Investigational Site
-
Usti nad Labem, Czech Republic, 401 13
- Pfizer Investigational Site
-
-
-
-
-
Angers cedex, France, 49033
- Pfizer Investigational Site
-
Caen cedex, France, 14033
- Pfizer Investigational Site
-
Dijon, France
- Pfizer Investigational Site
-
Limoges, France, 87042
- Pfizer Investigational Site
-
Nantes Cedex 2, France, 44202
- Pfizer Investigational Site
-
Paris Cedex 13, France, 75651
- Pfizer Investigational Site
-
St Herblain Cedex, France, 44805
- Pfizer Investigational Site
-
Strasbourg, France, 67065 Cedex
- Pfizer Investigational Site
-
Toulouse cedex 9, France, 31059
- Pfizer Investigational Site
-
Vandoeuvre Les Nancy, France, 54511
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Germany, 10117
- Pfizer Investigational Site
-
Bielefeld, Germany, 33611
- Pfizer Investigational Site
-
Bonn, Germany, 53105
- Pfizer Investigational Site
-
Essen, Germany, 45122
- Pfizer Investigational Site
-
Frankfurt, Germany, 60590
- Pfizer Investigational Site
-
Karlsruhe, Germany, 76137
- Pfizer Investigational Site
-
Muenchen, Germany, 80336
- Pfizer Investigational Site
-
-
-
-
-
Athens, Greece, 115 27
- Pfizer Investigational Site
-
Rio, Patras, Greece, 26500
- Pfizer Investigational Site
-
-
Attica
-
Athens, Attica, Greece, 11526
- Pfizer Investigational Site
-
-
Crete
-
Heraklion, Crete, Greece, 71 500
- Pfizer Investigational Site
-
-
Macedonia
-
Thessaloniki, Macedonia, Greece, 56 403
- Pfizer Investigational Site
-
-
-
-
-
Pokfulam, Hong Kong
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Hungary, 1122
- Pfizer Investigational Site
-
Budapest, Hungary, 1125
- Pfizer Investigational Site
-
Budapest, Hungary, 1529
- Pfizer Investigational Site
-
Debrecen, Hungary, 4032
- Pfizer Investigational Site
-
-
-
-
Karnataka
-
Bangalore, Karnataka, India, 560 034
- Pfizer Investigational Site
-
-
Kerala
-
Kochi, Kerala, India, 682 026
- Pfizer Investigational Site
-
-
Maharashtra
-
Pune, Maharashtra, India, 411 001
- Pfizer Investigational Site
-
-
Punjab
-
Chandigarh, Punjab, India, 160 012
- Pfizer Investigational Site
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302017
- Pfizer Investigational Site
-
-
-
-
-
Zerifin, Israel, 70300
- Pfizer Investigational Site
-
-
-
-
-
Lido di Camaiore (LU), Italy, 55043
- Pfizer Investigational Site
-
Milano, Italy, 20133
- Pfizer Investigational Site
-
Napoli, Italy, 81013
- Pfizer Investigational Site
-
Pavia, Italy, 27100
- Pfizer Investigational Site
-
-
-
-
-
Seoul, Korea, Republic of, 120-752
- Pfizer Investigational Site
-
Seoul, Korea, Republic of, 110-744
- Pfizer Investigational Site
-
-
-
-
-
Puebla, Mexico, 72530
- Pfizer Investigational Site
-
-
DF
-
Mexico, DF, Mexico, 14080
- Pfizer Investigational Site
-
-
-
-
-
Amstelveen, Netherlands, 1186 AM
- Pfizer Investigational Site
-
Den Haag, Netherlands, 2545 CH
- Pfizer Investigational Site
-
-
GLD
-
Tiel, GLD, Netherlands, 4002 WP
- Pfizer Investigational Site
-
-
GR
-
Groningen, GR, Netherlands, 9713 GZ
- Pfizer Investigational Site
-
-
-
-
-
Otwock, Poland, 05-400
- Pfizer Investigational Site
-
Wodzislaw Sl., Poland, 44-300
- Pfizer Investigational Site
-
-
-
-
-
Faro, Portugal, 8000-386
- Pfizer Investigational Site
-
Porto, Portugal, 4099-001
- Pfizer Investigational Site
-
Porto, Portugal, 4202
- Pfizer Investigational Site
-
Vila Nova de Gaia, Portugal, 4400
- Pfizer Investigational Site
-
-
-
-
-
Cape Town, South Africa, 7500
- Pfizer Investigational Site
-
Cape Town, South Africa, 7925
- Pfizer Investigational Site
-
Johannesburg, South Africa, 2193
- Pfizer Investigational Site
-
-
Gauteng
-
Parktown, Gauteng, South Africa
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Spain, 28007
- Pfizer Investigational Site
-
Madrid, Spain, 28041
- Pfizer Investigational Site
-
Santa Cruz de Tenerife, Spain, 38320
- Pfizer Investigational Site
-
Valencia, Spain, 46014
- Pfizer Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Pfizer Investigational Site
-
-
Madrid
-
Alcorcon, Madrid, Spain, 28922
- Pfizer Investigational Site
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Pfizer Investigational Site
-
-
-
-
-
Stockholm, Sweden, 118 83
- Pfizer Investigational Site
-
Uppsala, Sweden, 751 85
- Pfizer Investigational Site
-
-
-
-
-
Lausanne, Switzerland, CH-1011
- Pfizer Investigational Site
-
-
-
-
-
Taipei, Taiwan, 112
- Pfizer Investigational Site
-
-
-
-
-
London, United Kingdom, SE1 9RT
- Pfizer Investigational Site
-
Portsmouth, United Kingdom, PO3 6AD
- Pfizer Investigational Site
-
Sheffield, United Kingdom, S10 2SJ
- Pfizer Investigational Site
-
Surrey GU2 5XX, United Kingdom
- Pfizer Investigational Site
-
Swansea, United Kingdom, SA2 8QA
- Pfizer Investigational Site
-
-
Cornwall
-
Truro, Cornwall, United Kingdom, TR1 3LJ
- Pfizer Investigational Site
-
-
Devon
-
Exeter, Devon, United Kingdom, EX2 5DW
- Pfizer Investigational Site
-
-
-
-
Alaska
-
Little Rock, Alaska, United States, 72205
- Pfizer Investigational Site
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Pfizer Investigational Site
-
-
California
-
Chula Vista, California, United States, 91911
- Pfizer Investigational Site
-
La Mesa, California, United States, 91942
- Pfizer Investigational Site
-
Oceanside, California, United States, 92056
- Pfizer Investigational Site
-
Palm Springs, California, United States, 92262-4885
- Pfizer Investigational Site
-
San Diego, California, United States, 92123
- Pfizer Investigational Site
-
San Francisco, California, United States, 94115
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30342
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30309
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30322
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30306
- Pfizer Investigational Site
-
Decatur, Georgia, United States, 30033
- Pfizer Investigational Site
-
Fayetteville, Georgia, United States, 30214
- Pfizer Investigational Site
-
Macon, Georgia, United States, 31217
- Pfizer Investigational Site
-
Marietta, Georgia, United States, 30060
- Pfizer Investigational Site
-
Tucker, Georgia, United States, 30084
- Pfizer Investigational Site
-
-
Illinois
-
Rockford, Illinois, United States, 61104
- Pfizer Investigational Site
-
-
Indiana
-
Jefferson, Indiana, United States, 47130
- Pfizer Investigational Site
-
New Albany, Indiana, United States, 47150-6809
- Pfizer Investigational Site
-
-
Iowa
-
Cedar Rapids, Iowa, United States, 52403
- Pfizer Investigational Site
-
Dubuque, Iowa, United States, 52001
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Pfizer Investigational Site
-
Louisville, Kentucky, United States, 40202
- Pfizer Investigational Site
-
Louisville, Kentucky, United States, 40217
- Pfizer Investigational Site
-
Louisville, Kentucky, United States, 40241
- Pfizer Investigational Site
-
Louisville, Kentucky, United States, 40505-4816
- Pfizer Investigational Site
-
Shelbyville, Kentucky, United States, 40065
- Pfizer Investigational Site
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Pfizer Investigational Site
-
Gretna, Louisiana, United States, 70056
- Pfizer Investigational Site
-
Lafayette, Louisiana, United States, 70503
- Pfizer Investigational Site
-
Marrero, Louisiana, United States, 70006
- Pfizer Investigational Site
-
Marrero, Louisiana, United States, 70072
- Pfizer Investigational Site
-
Metairie, Louisiana, United States, 70006
- Pfizer Investigational Site
-
New Orleans, Louisiana, United States, 70115
- Pfizer Investigational Site
-
-
Maine
-
Biddeford, Maine, United States, 04005
- Pfizer Investigational Site
-
Brunswick, Maine, United States, 04011
- Pfizer Investigational Site
-
Scarborough, Maine, United States, 04074
- Pfizer Investigational Site
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01608
- Pfizer Investigational Site
-
-
Michigan
-
Allegan, Michigan, United States, 49010
- Pfizer Investigational Site
-
Ann Arbor, Michigan, United States, 48109-0848
- Pfizer Investigational Site
-
Ann Arbor, Michigan, United States, 48109
- Pfizer Investigational Site
-
Kalamazoo, Michigan, United States, 49007
- Pfizer Investigational Site
-
Kalamazoo, Michigan, United States, 49048
- Pfizer Investigational Site
-
St. Joseph, Michigan, United States, 49085
- Pfizer Investigational Site
-
-
Mississippi
-
Columbus, Mississippi, United States, 39705
- Pfizer Investigational Site
-
Corinth, Mississippi, United States, 38834
- Pfizer Investigational Site
-
Tupelo, Mississippi, United States, 38801
- Pfizer Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Pfizer Investigational Site
-
Omaha, Nebraska, United States, 68124
- Pfizer Investigational Site
-
Omaha, Nebraska, United States, 68130
- Pfizer Investigational Site
-
Papillion, Nebraska, United States, 68046
- Pfizer Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Pfizer Investigational Site
-
Las Vegas, Nevada, United States, 89106
- Pfizer Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Pfizer Investigational Site
-
Ruidoso, New Mexico, United States, 88345
- Pfizer Investigational Site
-
-
New York
-
Buffalo, New York, United States, 14263
- Pfizer Investigational Site
-
Great Neck, New York, United States, 11023
- Pfizer Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Pfizer Investigational Site
-
Brevard, North Carolina, United States, 28712
- Pfizer Investigational Site
-
Lexington, North Carolina, United States, 27292
- Pfizer Investigational Site
-
Winston-Salem, North Carolina, United States, 27103
- Pfizer Investigational Site
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Pfizer Investigational Site
-
Dover, Ohio, United States, 44622
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112-4491
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97227-1191
- Pfizer Investigational Site
-
-
Pennsylvania
-
Langhorne, Pennsylvania, United States, 19047
- Pfizer Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404-3324
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38120
- Pfizer Investigational Site
-
-
Texas
-
Arlington, Texas, United States, 76012
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75230
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75235-7786
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75235
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75390-8590
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75390-9015
- Pfizer Investigational Site
-
Richardson, Texas, United States, 75080
- Pfizer Investigational Site
-
Trophy Club, Texas, United States, 76262
- Pfizer Investigational Site
-
-
Utah
-
Bountiful, Utah, United States, 84010
- Pfizer Investigational Site
-
Layton, Utah, United States, 84041
- Pfizer Investigational Site
-
Murray, Utah, United States, 84107
- Pfizer Investigational Site
-
Provo, Utah, United States, 84604
- Pfizer Investigational Site
-
Salt Lake City, Utah, United States, 84106
- Pfizer Investigational Site
-
WVC, Utah, United States, 84120
- Pfizer Investigational Site
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Pfizer Investigational Site
-
-
Washington
-
Everett, Washington, United States, 98201
- Pfizer Investigational Site
-
Kennewick, Washington, United States, 99336
- Pfizer Investigational Site
-
Richland, Washington, United States, 99352
- Pfizer Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-5666
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Advanced Non-Small-Cell Lung Cancer (NSCLC) stage IIIB with pleural effusion or stage IV
- No prior systemic treatment for Non-Small-Cell Lung Cancer (NSCLC)with chemotherapy, immunotherapy, biologic response modifiers or other investigational drugs
- Eastern Cooperative Oncology Performance Status (ECOG PS) 0 or 1
Exclusion Criteria:
- Small cell or carcinoid lung cancer
- Known Central Nervous System (CNS) metastasis
- Pre-existing auto-immune or antibody mediated diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Standard of care chemotherapy plus experiment intervention (PF-3512676)
|
Other Names:
|
Active Comparator: B
Standard of care chemotherapy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: 656 Events
|
656 Events
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Objective Response
Time Frame: End of Treatment
|
End of Treatment
|
Time to Tumor Progression
Time Frame: Time of progressive disease
|
Time of progressive disease
|
Progression Free Survival
Time Frame: Time of primary endpoint
|
Time of primary endpoint
|
Duration of Response
Time Frame: Time of progressive disease
|
Time of progressive disease
|
Patient Reported Outcomes
Time Frame: End of Treatment
|
End of Treatment
|
Overall Safety Profile
Time Frame: 28 days post PF-3512676 dosing
|
28 days post PF-3512676 dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
November 15, 2005
First Submitted That Met QC Criteria
November 15, 2005
First Posted (Estimate)
November 17, 2005
Study Record Updates
Last Update Posted (Estimate)
March 30, 2015
Last Update Submitted That Met QC Criteria
March 10, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- A8501001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on PF-3512676 + Paclitaxel + Carboplatin
-
PfizerCompletedMelanoma | Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Lymphoma, T-CellUnited States, Germany
-
PfizerCompletedCarcinoma, Non-Small Cell LungUnited States, Canada, Germany
-
PfizerTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Ronald LevyPfizerCompletedLymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-CellUnited States
-
Ronald LevyAmerican Society of Clinical Oncology; Lymphoma Research FoundationCompletedMycosis Fungoides | Non-Hodgkin LymphomaUnited States
-
zr Pharma & GmbHFoundation MedicineCompletedOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerUnited Kingdom, United States, Israel, Spain, Italy, Czechia, Canada, Hungary, Poland, Russian Federation, Brazil, Ukraine
-
PfizerWithdrawn
-
PfizerCompletedCarcinoma, Metastatic BreastUnited States
-
Shengjing HospitalRecruiting